Scarica il documento in formato pdf (574 KB - ANCE

More documents

Recommendations

Info

and Hispanic origin: (Updated 11/2002). Data from Centers for Disease Control and Prevention, National Center for Health Statistics, National Health and Nutrition Examination Survey, Hispanic Health and Nutrition Examination Survey and National Health Examination Survey 5. Mancia G. Lo studio ALLHAT: contributi, limiti e prospettive. Ital Heart J Suppl 2003; 4 (2): 77-84 6. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003 May; 16(5):407-415 7. Meltzer JI. A specialist in clinical hypertension critiques ALLHAT. Am J Hypertens 2003 May; 16(5):416-420 8. Wing LMH, Reid CM, Ryan PA et al. Comparison of Outcomes with Angiotensin- Converting-Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. N Engl J Med 2003; 348(7): 583-592 9. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-412 10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264 11. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP- Hypertension). Lancet 1991;338:1281-1285 12. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110. 13. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. 14. Hypertension Detection and Follow-up Program. The effect of treatment on mortality in ‘mild’ hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982; 307:976–980 15. Zanchetti A, Hansson L, Menard J et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19:819–825 16. Levy D, Salomon M, D’Agostino RB et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786–1793 17. Mathew J, Sleight P, Lonn E et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615–1621 18. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616. 19. Cook NR, Cohen J, Hekbert PR et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701–09. 20. Vasan RS, Beiser A, Seshadri S et al. Residual lifefetime risk for developing hyeprtension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-1010 21. Guidelines Committee - 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003, 21:1011–1053 22. Terpstra WL, May JF, Smit AJ et al. Longterm effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19:303–309 23. Devereux RB, Palmieri V, Sharpe N et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104:1248–1254 24. Thurmann PA, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037–2042 25. Malmqvist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167–1176 26. Dahlof B, Zanchetti A, Diez J et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855–1864 27. Lithell H, Hansson L, Skogg I et al. for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principalresults of a randomised double- S. Lino Ipertensione arteriosa 39
40 Giornale Italiano di Cardiologia Pratica It J Practice Cardiol Ottobre 2003 blind intervention trial. J Hypertens 2003; 21; 875–886 28. Dickstein K, Kjekshus J, and the OPTI- MAAL Steering Committee, for the OPTI- MAAL Study Group.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet, 2002. 29. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429 –1435 30. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676 31. Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003 Mar 11;107(9):1291-6 32. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366–372 33. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503–1510 34. Simon A, Garie´ py J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103:2949–2954 35. Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JA- MA 1996; 276:785–791. 36. Zanchetti A, Agabiti Rosei E, Dal Palu C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16:1667–1676 37. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869 38. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851–860 39. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870–878 40. Hennekens CH. Risk factors for coronary heart disease in women. Cardiol Clin 1998 Feb;16(1):1-8 41. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J 2001 Feb;141(2 Suppl):S58- 62
Page 2 and 3: Giornale Italiano di Cardiologia Pr
Page 4 and 5: Indice Editoriale Pag. 4 L. Pagliar
Page 6 and 7: il caso di ricordare che siamo nell
Page 8 and 9: Risk prediction in heart surgery: m
Page 10 and 11: factors were compared based on the
Page 12 and 13: Overestimation Mortality (%) Mortal
Page 14 and 15: spital mortality of patients who re
Page 16 and 17: weeks and months later after discha
Page 18 and 19: Precocità degli interventi prevent
Page 20 and 21: NON FUMARE! FAI CONTENTO IL TUO CUO
Page 22 and 23: Aspetti clinici, diagnosi ECG, indi
Page 24 and 25: della frequenza. Le restanti tachic
Page 26 and 27: Aritmia Risposta alle manovre Modal
Page 28 and 29: Terapia Le alternative terapeutiche
Page 30 and 31: Le Figure 3,4 e 5 mostrano la local
Page 32 and 33: Istituzione di “Stroke Unit” ne
Page 34 and 35: evitabile. Questo tempo è molto pi
Page 36 and 37: potrebbero annullare gli effetti po
Page 38 and 39: fatti dimostrato che la sola differ
Page 42 and 43: Cooperazione biventricolare negli a
Page 44 and 45: stata successivamente indicizzata p
Page 46 and 47: Variabile Controlli Atleti P ANULUS
Page 48 and 49: Tenuto conto che il picco di veloci
Page 50 and 51: ventricular myocardial function in
Page 52 and 53: differenti regimi antipertensivi, c
Page 54 and 55: Prevenzione della morte improvvisa
Page 56 and 57: BIBLIOGRAFIA 1. Davies MJ. The card
Page 58 and 59: sali di 0,7-0,8, si avvicina o supe
Page 60 and 61: Classe III 1. Sincope di causa non
Page 62 and 63: Nuovi paradigmi interpretativi dell
Page 64 and 65: Queste tre fasi sono le fasi extrac
Page 66 and 67: 9. Libby P. Molecular bases of the
Page 68 and 69: nale con risultati positivi misurab
Page 70 and 71: (0,625 mg. di estrogeno e 2,5 mg. d
Page 72 and 73: 5-8 Ottobre - Napoli, Italia 105°
Page 74 and 75: CORSO TEORICO-PRATICO ALLA DEFIBRIL

Scarica il documento in formato pdf (574 KB - ANCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?